Pediatric liver transplantation outcomes from a single center in Thailand

Table 1 Patient characteristics

Data set		Living donors (n = 77)	Deceased donors (n = 17)	Total (n = 94)
Sex	Male (n, %)	36 (46.8)	7 (41.2)	43 (45.7)
Age (yr)1	Median (IQR)	1.1 (0.8-1.9)	9.7 (3.5-13.5)	1.2 (0.8-3.8)
Diagnosis of biliary atresia (n, %)		59 (76.6)	11 (64.7)	70 (74.5)
PELD score (age < 12 yr, n = 84)	Median (IQR)	19 (12.5-26)	25 (17.5-31.3)	20 (13-26.8)
	n	74	10	84
MELD score (age ≥ 12 yr, n = 10)	Median (IQR)	19 (18-19)	23 (15-30)	19.5 (15.8-26.3)
	n	3	7	10
Wait time (mo)2	Median (IQR)	1.6 (0.3–3.1)	11.2 (2.1–33.3)	1.7 (0.4–4.0)

¹P < 0.001.

²P = 0.01.

PELD: Pediatric end-stage liver disease, MELD: Model for end-stage liver disease.

Table 2 Donor and recipient laboratory findings

Data set		Living donors (n = 77)	Deceased donors (n = 17)	Total (n = 94)
ABO incompatibility1	n, %	8 (10.4)	0 (0)	8 (8.5)
Positive donor anti-HBc	n, %	4 (5.2)	4 (23.5)	8 (8.5)
Anti-CMV IgG (n, %)2	D+/R-	8 (11.0)	2 (18.2)	10 (11.9)
	D+/R+	62 (84.9)	9 (81.8)	71 (84.5)
	D-/R+	3 (4.1)	0 (0)	3 (3.6)
	D-/R-	0 (0)	0 (0)	0 (0)
Recipient positive serology (n/total, %)	HBsAg	0/44 (0)	0/9 (0)	0/53 (0)
	Anti-HBs	33/43 (76.7)	3/10 (30)	36/53 (67.9)
	Anti-HBc	3/44 (6.8)	2/10 (20)	5/54 (9.3)
	Anti-HCV	1/42 (2.4)	0/10 (0)	1/52 (1.9)
	Anti-EBV IgG	31/43 (72.1)	8/9 (88.9)	39/52 (75)

¹Median age at liver transplantation (IQR) = 0.9 (0.5-1.0) years.

²Total 84 patients.

D: Donor; R: Recipient; HBsAg: Hepatitis B surface antigen; Anti-HBs: Hepatitis B surface antibody; Anti-HBc: Hepatitis B core antibodies; Anti-HCV: Hepatitis C virus antibodies; Anti-EBV: Epstein-Barr virus antibodies.